Jun. 24 at 3:54 PM
$TELO $TELO Why have we evaluated Telomir-Zn across multiple cancer models?
Because many cancers share common biological drivers.
Across preclinical studies, Telomir-Zn has demonstrated activity in triple-negative breast cancer (TNBC), pancreatic cancer, aggressive prostate cancer, and leukemia models.
The common thread is not the cancer type itself, but the biology. Many tumors rely on dysregulated iron metabolism, epigenetic alterations, and metabolic adaptations to support growth, survival, and treatment resistance.
Telomir-Zn is being investigated for its ability to modulate intracellular metal-dependent pathways involved in gene regulation, cellular metabolism, and tumor biology.
While TNBC remains the lead clinical development program, the growing body of preclinical evidence continues to support evaluation of this mechanism across multiple oncology settings.
